Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Type 1 diabetes patients sought for UT Southwestern clinical drug trial

UT Southwestern Medical Center researchers are recruiting individuals newly diagnosed with type 1 diabetes for a clinical trial to gauge the effectiveness of adding an investigational stem cell product to standard insulin therapy.

3 Mar 2009

Biphasic insulin provides significant improvements in more than 52,000 diabetic patients

A major international diabetes study of more than 52,000 patients from eight countries has shown that using biphasic BIAsp 30 insulin resulted in significant clinical improvements and greater patient satisfaction.

2 Mar 2009

Revealing statistics about childhood diabetes reported

The incidence rate of type 1 diabetes among non-Hispanic white youth in the United States is one of the highest in the world, according to a major national study coordinated by researchers at Wake Forest University Baptist Medical Center.

1 Mar 2009

Team-based diabetes care fetches more value for dollar

Diabetes patients undergoing team-based care do not save more in treatment costs under Medicare and Medicaid than other patients, but they are healthier, according to a recent study.

26 Feb 2009

How obesity, diet and exercise influence our metabolism and interact with our genome

Research by kinesiology investigator Dustin Hittel, PhD, has proven that muscle in extremely obese individuals produces large amounts of a protein called myostatin, which normally inhibits muscle growth-suggesting that for Type 2 diabetics, and the very obese, the task of getting healthy may be more difficult than initially thought.

26 Feb 2009

Liver tumors associated with metabolic syndrome differ from other tumors

Liver cancer in patients whose only risk factor is metabolic syndrome has distinct forms and structures compared to other liver tumors.

25 Feb 2009

Compounds that trigger beta cell replication identified

Researchers at the Genomics Institute of the Novartis Research Foundation (GNF) have identified a set of compounds that can trigger the proliferation of insulin-producing cells in the pancreas, using sophisticated high-throughput screening techniques.

25 Feb 2009

Could our mother's diet at time we are conceived set the course for our future health?

This intriguing question is at the heart of a new study based on an "experiment of nature" being conducted by Wellcome Trust-funded researchers.

25 Feb 2009

Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes

Researchers at the University of Vermont Cardiovascular Research Institute, Colchester, Vermont have found that increased expression in the heart of plasminogen activator inhibitor type-1 (PAI-1) is profibrotic.

24 Feb 2009

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss.

24 Feb 2009

Scientists mine drugs database for new diabetes treatment

Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process.

22 Feb 2009

Investing in personalized medicine will benefit Canada

Canada has the opportunity to be an international leader in personalized medicine and needs to invest in this area for the health of Canadians and to reap the benefits of job creation, writes Dr. Thomas Hudson in a commentary http://www.cmaj.ca/cgi/rapidpdf/cmaj.1090199 released online today in CMAJ ( Canadian Medical Association Journal ).

20 Feb 2009

GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication

GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.

18 Feb 2009